Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma
Molecular Oncology · 2023-10 · 17 (10) · 2168-2182
DOI: 10.1002/1878-0261.13503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 30.08.2023. Verfasst von Mayu Nakagawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Myosin Heavy Chains, Phosphoproteins, Adenocarcinoma, Clear Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Kitasato University School of Allied Health Sciences Grant-in-Aid for Research Project.
Abstract (Originalsprache)
Ezrin‐radixin‐moesin‐binding phosphoprotein 50 (EBP50) is a scaffold protein that is required for epithelial polarity. Knockout (KO) of membranous EBP50 (Me‐EBP50) in ovarian clear cell carcinoma (OCCC) cells induced an epithelial–mesenchymal transition (EMT)‐like phenotype, along with decreased proliferation, accelerated migration capability, and induction of cancer stem cell (CSC)‐like properties. Shotgun proteomics analysis of proteins that co‐immunoprecipitated with EBP50 revealed that Me‐EBP50 strongly interacts with myosin 9 (MYH9). Specific inhibition of MYH9 with blebbistatin phenocopied Me‐EBP50 KO, and blebbistatin treatment potentiated the effects of Me‐EBP50 KO. In OCCC cells from clinical samples, Me‐EBP50 and MYH9 were co‐localized at the apical plasma membrane. Patients with a combination of Me‐EBP50‐high and MYH9‐high scores had the best prognosis for overall and progression‐free survival. Our data suggest that Me‐EBP50 has tumor‐suppressive effects through the establishment and maintenance of epithelial polarization. By contrast, loss of Me‐EBP50 expression induces EMT‐like phenotypes, probably due to MYH9 dysfunction; this results in increased cell mobility and enhanced CSC‐like properties, which in turn promote OCCC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
- Department of Pathology, Kitasato University School of Allied Health Science, Sagamihara, Japan.
- Center for Disease Proteomics, School of Science, Kitasato University, Sagamihara, Japan.
ORCID-Profile: Makoto Saegusa
Förderung
- JSPS KAKENHI
- Kitasato University School of Allied Health Sciences Grant-in-Aid for Research Project
Zitieren
APA
Nakagawa, M., Matsumoto, T., Yokoi, A., Hashimura, M., Oguri, Y., Konno, R., Ishibashi, Y., Ito, T., Ohhigata, K., Harada, Y., Fukagawa, N., Kodera, Y., & Saegusa, M. (2023). Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma. Molecular Oncology, 17(10), 2168-2182. https://doi.org/10.1002/1878-0261.13503
Vancouver
Nakagawa M, Matsumoto T, Yokoi A, Hashimura M, Oguri Y, Konno R, et al. Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma. Molecular Oncology. 2023;17(10):2168-2182. doi:10.1002/1878-0261.13503
BibTeX
@article{Nakagawa2023,
author = {Nakagawa, Mayu and Matsumoto, Toshihide and Yokoi, Ako and Hashimura, Miki and Oguri, Yasuko and Konno, Ryo and Ishibashi, Yu and Ito, Takashi and Ohhigata, Kensuke and Harada, Yohei and Fukagawa, Naomi and Kodera, Yoshio and Saegusa, Makoto},
title = {Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma},
journal = {Molecular Oncology},
year = {2023},
volume = {17},
number = {10},
pages = {2168--2182},
doi = {10.1002/1878-0261.13503}
}
EUVIMED